Literature DB >> 11151420

Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.

T H Haapaniemi1, M A Kallio, J T Korpelainen, K Suominen, U Tolonen, K A Sotaniemi, V V Myllylä.   

Abstract

Autonomic nervous system (ANS) involvement is frequently found in Parkinson's disease (PD), but its causal relationship to the disease itself and its medication is unclear. We evaluated the effects of PD medications on cardiovascular ANS functions. Heart rate (HR) responses to normal and deep breathing, the Valsalva manoeuvre and tilting, and blood pressure (BP) responses to tilting and isometric work were measured prospectively in 60 untreated PD patients randomised to receive either levodopa (n = 20), bromocriptine (n = 20) or selegiline (n = 20) as their initial treatment. The results were compared with those of 28 healthy controls. The responses were recorded at baseline, after 6 months on medication and following a 6-week washout period. At baseline HR responses to normal breathing, deep breathing and tilting were already lower and the fall in the systolic BP immediately and at 5 min after tilting was more pronounced in the PD patients than in the controls. Six months' levodopa treatment diminished the systolic BP fall after tilting when compared to baseline, whereas bromocriptine and selegiline increased the fall in systolic BP after tilting and selegiline diminished the BP responses to isometric work. The BP responses returned to the baseline values during the washout period. The drugs induced no change in the HR responses. Thus PD itself causes autonomic dysfunction leading to abnormalities in HR and BP regulation and the PD medications seem to modify ANS responses further. Bromocriptine and selegiline, in contrast to levodopa, increase the orthostatic BP fall and suppress the BP response to isometric exercise reflecting mainly impairment of the sympathetic regulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11151420     DOI: 10.1007/s004150070075

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Determinants of autonomic dysfunction in idiopathic Parkinson's disease.

Authors:  Alexei Korchounov; Kirn R Kessler; Nikolay N Yakhno; Igor V Damulin; Hayo I Schipper
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

2.  Skin biopsy for assessment of autonomic denervation in Parkinson's disease.

Authors:  R Dabby; R Djaldetti; M Shahmurov; T A Treves; B Gabai; E Melamed; M Sadeh; I Avinoach
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 3.  Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.

Authors:  James J Gugger
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

Review 4.  Monoamine oxidase B inhibitors for early Parkinson's disease.

Authors:  A D Macleod; C E Counsell; N Ives; R Stowe
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

Review 5.  Orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism.

Authors:  Seyed-Mohammad Fereshtehnejad; Johan Lökk
Journal:  Parkinsons Dis       Date:  2014-02-02

6.  Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension.

Authors:  Andrea Sturchio; Alok K Dwivedi; Luca Marsili; Aaron Hadley; Gabriele Sobrero; Dustin Heldman; Simona Maule; Leonardo Lopiano; Cristoforo Comi; Maurizio Versino; Alberto J Espay; Aristide Merola
Journal:  J Neurol       Date:  2020-09-26       Impact factor: 4.849

7.  The management of orthostatic hypotension in Parkinson's disease.

Authors:  Alvaro Sánchez-Ferro; Julián Benito-León; Juan Carlos Gómez-Esteban
Journal:  Front Neurol       Date:  2013-06-10       Impact factor: 4.003

8.  Orthostatic stability with intravenous levodopa.

Authors:  Shan H Siddiqi; Mary L Creech; Kevin J Black
Journal:  PeerJ       Date:  2015-08-27       Impact factor: 2.984

Review 9.  The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review.

Authors:  Panagiotis Zis; Roberto Erro; Courtney C Walton; Anna Sauerbier; Kallol Ray Chaudhuri
Journal:  NPJ Parkinsons Dis       Date:  2015-07-09

10.  Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson's disease.

Authors:  Kai Li; Rocco Haase; Heinz Rüdiger; Manja Reimann; Heinz Reichmann; Martin Wolz; Tjalf Ziemssen
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.